The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs. “In this scheme, CanaRx facilitates foreign physicians rewriting the employee’s U.S. prescription, and then supplies the employee with unapproved versions of FDA-approved drugs purportedly sourced from Canada, the United Kingdom or Australia that are represented to have undergone review from those countries’ drug regulatory systems,” FDA said. “This is particularly troublesome, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s ‘insurance’ plan and may not question their legitimacy.” The letter lists more than 150 websites affiliated with the company. FDA said health care providers and consumers should report any adverse events related to drugs provided by CanaRx to its MedWatch program.

Related News Articles

Headline
The AHA Sept. 24 expressed support for the Medical Student Education Authorization Act (H.R. 5428), legislation introduced in the House Sept. 17 that would…
Headline
The AHA expressed support Sept. 22 to House and Senate sponsors of the Medicare Advantage Prompt Pay Act (H.R. 5454/S. 2879), legislation that would apply a…
Headline
The Senate Sept. 19 failed to adopt a continuing resolution by a 44-48 vote  that would have funded the government through Nov. 21. The CR was passed by…
Headline
The House Appropriations Committee today released bill text for a continuing resolution to fund the government through Nov. 21. The bill also extends key…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
Newsweek’s Access Health newsletter today features a conversation with AHA Chair Tina Freese Decker, president and CEO of Corewell Health in Michigan, where…